MedTrace Logo

Apatinib for Resectable Colorectal Cancer

NCT03228043 · Status: WITHDRAWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2024-11-14

No results posted yet for this study

Summary

Objective: To compare the outcome of patients with colorectal cancer who treated with adjuvant therapy or Apatinib with adjuvant therapy postoperatively.

Language: English.

Conditions

Interventions

DRUG

Apatinib

Apatinib combine with CAPEOX adjuvant chemotherapy for resectable colorectal

DRUG

CAPEOX

CAPEOX adjuvant chemotherapy for resectable colorectal

Sponsors & Collaborators

  • Nanchong Central Hospital

    lead OTHER_GOV

Principal Investigators

  • Yunhong Tian · Nanchong Central Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-01
Primary Completion
2021-03-01
Completion
2023-03-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03228043 on ClinicalTrials.gov